Exploratory secondary analysis of ANDROMEDA-SHOCK-2 (1363 septic shock patients): norepinephrine-equivalent >0.5 µg/kg/min at 6 h plus capillary refill >3 s and non-falling lactate marked 28-day mortality of 73.6% vs 23.7% (aHR 4.68), outperforming dose alone.
Secondary analysisn = 1,363
Kattan et al. Persistent tissue hypoperfusion improves risk stratification beyond vasopressor dose in refractory septic shock: a secondary analysis of the ANDROMEDA-SHOCK-2 trial